Investors & Media

OTCQB: INTI
PRICE:
Stock Info
Our Story

Inhibitor Therapeutics, we are a publicly traded, clinical stage pharmaceutical development company. We have a focus on developing and commercializing innovative therapies, using repurposed, already approved API’s (active pharmaceutical ingredients) that have clinical value and are patent protected. We have a significant amount of owned intellectual property around the use of itraconazole in oncology indications, especially in the treatment of Basal Cell Carcinoma Nevus Syndrome and both lung and prostate cancers.

Recent News
Jan 22, 2020

INHIBITOR Therapeutics, Inc. (OTCQB: INTI), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to inhibit progression of cancerous...

Nov 25, 2019

INHIBITOR Therapeutics, Inc. (OTCQB: INTI), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to inhibit progression of cancerous...

Events & Presentations
Get Important News and Updates by Email
* Required Fields